Welcome to the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference 2026, where biologics, precision medicine, and pharmaceutical innovation come together.
Join Us!
May 12, 2026
Location: Sheraton San Diego Resort, San Diego, CA
About AAPS:
The American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC) 2026 brings together leading experts in biologics, drug development, and pharmaceutical sciences from May 11–14 in San Diego.
This premier biotechnology conference explores emerging trends in advanced therapies, precision medicine, and innovative modalities, offering scientific sessions, poster presentations, and networking opportunities that drive collaboration and accelerate innovation across the global biotech ecosystem.
We invite you to be part of the conversations shaping the future of biotechnology and pharmaceutical innovation. Join industry leaders, researchers, and innovators as they explore new ideas, exchange knowledge, and drive meaningful impact across the life sciences landscape.
Embedding AI/ML through Ethical and Regulatory Strategy in Precision Therapeutics
Artificial intelligence is poised to redefine how pharmaceutical scientists approach translational medicine and precision therapeutics, yet many challenges remain in moving from conceptual enthusiasm to compliant, scalable implementation. This Hot Topic session, AI by Design, Embedding Ethical and Regulatory Strategy into Precision Therapeutics, will explore how AI can be strategically integrated into drug development with equal emphasis on innovation, ethics, and regulatory alignment.
This presentation is designed for pharmaceutical scientists and industry professionals who are directly engaged in translational medicine, clinical development, and the advancement of precision therapeutics. It will be especially valuable for individuals seeking practical frameworks for adopting artificial intelligence in ways that align with evolving FDA and ICH regulatory guidance.
The presetation is also relevant for data scientists and computational modelers who are developing or applying AI-driven analytics to accelerate biomarker discovery, predictive immunogenicity, and real-world evidence integration. Biopharmaceutical executives, decision-makers, and R&D strategists will leave with a strategic perspective on how to responsibly scale AI-enabled innovation from discovery through commercialization.
Presenter
